Pfizer Global Research and Development - Articles and news items

Cell-based imaging

Issue 5 2006, Past issues / 28 September 2006 / Jinghai J. Xu, Ph.D., Margaret C. Dunn, Arthur R. Smith, Pfizer Global Research and Development

Traditionally, in vivo histopathological findings have been used as part of standard readouts for safety assessment of new chemical entities (NCEs). The process typically involves dosing animals with NCEs for varying amounts of time, harvesting their major organs at the end of the study, preparing tissue sections and slides and visual examination of these slides by trained pathologists.

Identifying human toxicity potential

Issue 4 2006, Past issues / 20 July 2006 / Dolores Diaz, CEREP and Peter J. O’Brien, Safety Sciences Europe, Pfizer Global R&D

The statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors) are drugs that inhibit cholesterol biosynthesis by blocking the formation of the cholesterol precursor mevalonate. Statins are the most effective cholesterol-lowering agents available and are considered the first line of treatment for most patients with high serum cholesterol levels1.

The promise of pancreatic beta cells

Issue 2 2005, Past issues / 20 May 2005 / William Carley, Ph.D., Experimental Medicine, Pfizer Global R&D

Biomarker application during drug development is driven by the need to define disease and therapeutic efficacy/safety earlier, better and with reduced cost.

Evaluating drug safety

Issue 1 2005, Past issues / 7 March 2005 / Donald G. Robertson, Metabonomics Evaluation Group, Departments of Worldwide Safety Sciences and Michael D. Reily, Discovery Technologies, Pfizer Global Research and Development

Metabonomics has been defined as the “the quantitative measurement of the time-related multi-parametric metabolic response of living systems to pathophysiological stimuli or genetic modification”1. In simple terms it is a powerful tool for assessing the metabolic component of systemic response.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...